National estimates of the prevalence of Alzheimer's disease in the United States.
Several methods of estimating prevalence of dementia are presented in this article. For both Brookmeyer and the Chicago Health and Aging project (CHAP), the estimates of prevalence are derived statistically, forward calculating from incidence and survival figures. The choice of incidence rates on which to build the estimates may be critical. Brookmeyer used incidence rates from several published studies, whereas the CHAP investigators applied the incidence rates observed in their own cohort. The Aging, Demographics, and Memory Study (ADAMS) and the East Boston Senior Health Project (EBSHP) were sample surveys designed to ascertain the prevalence of Alzheimer's disease and dementia. ADAMS obtained direct estimates by relying on probability sampling nationwide. EBSHP relied on projection of localized prevalence estimates to the national population. The sampling techniques of ADAMS and EBSHP were rather similar, whereas their disease definitions were not. By contrast, EBSPH and CHAP have similar disease definitions internally, but use different calculation techniques, and yet arrive at similar prevalence estimates, which are considerably greater than those obtained by either Brookmeyer or ADAMS. Choice of disease definition may play the larger role in explaining differences in observed prevalence between these studies.
Department of Biostatistics, University of California, Los Angeles, USA. rbrookmeyer@ucla.edu
Ron
R
Brookmeyer
Denis A
DA
Evans
Liesi
L
Hebert
Kenneth M
KM
Langa
Steven G
SG
Heeringa
Brenda L
BL
Plassman
Walter A
WA
Kukull
D000367:Age Factors; D000544:Alzheimer Disease / Q000453:epidemiology*; D018672:Community Health Planning; D003625:Data Collection; D006801:Humans; D015994:Incidence; D015233:Models, Statistical; D015995:Prevalence; D012494:Sampling Studies; D014481:United States / Q000453:epidemiology
Alzheimers Dement. 2008 Sep;4(5):316-23
18790458
Alzheimers Dement. 2007 Jul;3(3):186-91
19595937
Arch Neurol. 2003 Oct;60(10):1385-9
14568808
Neurology. 2001 Nov 13;57(9):1655-62
11706107
Neurology. 1984 Jul;34(7):939-44
6610841
Lancet. 1997 Jun 21;349(9068):1793-6
9269213
Neurology. 1993 Mar;43(3 Pt 1):515-9
8450993
Lancet. 2005 Dec 17;366(9503):2112-7
16360788
Neurology. 2001 Jan 9;56(1):37-42
11148233
Lancet. 2006 Apr 15;367(9518):1262-70
16631882
Alzheimers Dement. 2008 Mar;4(2):110-33
18631956
Neurology. 1988 Jun;38(6):975-80
3368079
Age Ageing. 1996 May;25(3):201-5
8670552
Neurology. 2000 Jun 13;54(11):2072-7
10851365
Arch Neurol. 2003 Aug;60(8):1119-22
12925369
Neurology. 2007 Dec 11;69(24):2197-204
17568013
JAMA. 1989 Nov 10;262(18):2551-6
2810583
Int J Neurosci. 1991 Apr;57(3-4):167-78
1938160
Neuroepidemiology. 2007;29(1-2):125-32
17975326
JAMA. 1995 May 3;273(17):1354-9
7715060
Alzheimers Dement. 2011 Jan;7(1):35-52
21255742
Milbank Q. 1990;68(2):267-89
2233632
Lancet Neurol. 2010 Jan;9(1):119-28
20083042
Ann Intern Med. 2008 Mar 18;148(6):427-34
18347351
Stat Med. 2000 Jun 15-30;19(11-12):1481-93
10844713
Dialogues Clin Neurosci. 2004 Dec;6(4):401-8
22034212
J Am Geriatr Soc. 1998 Dec;46(12):1576-7
9848822
Neurology. 1993 Nov;43(11):2412-4
8232972
Acta Psychiatr Scand. 1987 Nov;76(5):465-79
3324647
Am J Public Health. 1998 Sep;88(9):1337-42
9736873
Arch Neurol. 2002 Nov;59(11):1764-7
12433264
Alzheimers Dement. 2010 Sep;6(5):425-8
20691645
Neuroepidemiology. 2005;25(4):181-91
16103729
Arch Neurol. 2003 Feb;60(2):185-9
12580702
Alzheimers Dement. 2011 Jan;7(1):15-34
21255741